• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 4Dose effects of pegylated interferon, trials of with dual therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirina

Author
Country
N
Quality
Population CharacteristicsPercent Genotype 2 or 3Weekly Pegylated Interferon DoseDaily Ribavirin DoseDurationSustained Virologic Response Among Genotype 2 or 3
Trials of Higher vs. Lower Doses of Pegylated Interferon Alfa-2b
Abergel, 200673
France
N=78 with genotype 2 or 3 infection
N(total)=203

Quality: Fair
A vs. B
Age (mean): 50 vs. 52 years
Female: 36% vs. 32%
Race: Not reported
Cirrhosis: 46% vs. 57%
Minimal or no fibrosis: Not reported
38%A. Alfa-2b 1.5 mcg/kg
B. Alfa-2b 0.75 mcg/kg
800 mg48 weeksA. 73%
B. 73%
Kawaoka, 200974
Japan
N=53

Quality: Fair
A vs. B
Age (median): 57 vs. 55 years
Female: 65% vs. 44%
Race: Not reported (study conducted in Japan)
Cirrhosis: None
Minimal or no fibrosis: 55% vs. 48%
100%A. Alfa-2b 1.0 mcg/kg
B. Alfa-2b 1.5 mcg/kg
600–1000 mg24 weeksA. 39%
B. 74%
Krawitt, 200675
U.S.
N=86 with genotype 2 or 3 infection
N(total) = 301

Quality: Fair
A vs. B
Age >50 years: 18% vs. 19%
Female: 38% vs. 36%
Non-White race: 4.6% vs. 3.1%
Cirrhosis: 17% vs. 10%
Minimal or no fibrosis: 30% vs. 33%
29%A. Alfa-2b 50 mcg
B. Alfa-2b 100–150 mcg
1000 mg48 weeksA. 56%
B. 65%
Meyer-Wyss, 200676
Switzerland
N=91 with genotype 2 or 3 infection
N(total)=219

Quality: Poor
A vs. B
Age (median): 39 vs. 42 years
Female: 43% vs. 28%
Race: Not reported
Cirrhosis: None
Minimal or no fibrosis: 58% vs. 49%
42%A. Alfa-2b 1.0 mcg/kg
B. Alfa-2b 1.5 mcg/kg
800 mg24–48 weeks by genotypeA. 71%
B. 81%
Sood, 200877
India
N=103

Quality: Fair
A vs. B
Age (mean): 43 vs. 37 years
Female: 12% vs. 22%
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported
100%A. Alfa-2b 1.0 mcg/kg
B. Alfa-2b 1.5 mcg/kg
10–12 mg/kg24 weeksA. 79%
B. 93%
Manns, 201166
International
N=454 (24 week)
N(total)=602

Quality: Poor
A vs. B
Age (Mean): 40 vs. 39 vs. years
Female: 35% vs. 40% vs.
Non-White race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported
100%A: Alfa-2b 1.5 mcg
B: Alfa-2b 1.0 mcg
800–1400 mg24 weeksA. 67%
B. 64%
Trials of Induction Dosing Regimens
Manns, 200178
U.S. & UK
N=1530

Quality: Fair
A vs. B
Age (mean):
Female:
Non-White race:
Cirrhosis: Not reported (29% vs. 30% severe fibrosis or cirrhosis)
Minimal or no fibrosis: Not reported
29%A. Alfa-2b 1.5 mcg/kg × 4 weeks, then 0.5 mcg/kg × 44 weeks
B. Alfa-2b 1.5 mcg/kg × 48 weeks
A. 1000–1200 mg
B. 800 mg
48 weeksA. 80%
B. 88%
Mimidis, 200679
Greece
N=120

Quality: Poor
A vs. B
Age (mean): Not reported
Female: : 49% vs. 51%
Race: Not reported
Cirrhosis: Not reported
Minimal or no fibrosis: Not reported
51%A. Alfa-2b 3.0 mcg/kg × 12 weeks, 1.5 mcg/kg × 36 weeks
B. Alfa-2b 1.5 mcg/kg × 48 weeks
800–1200 mg48 weeksA. 48%
B. 59%

HCV = hepatitis C virus; NA = not applicable; SD = standard deviation; U.K. = United Kingdom; U.S. = United States.

Note: Cirrhosis = METAVIR F4, Ishak 5–6, or equivalent. Minimal or no fibrosis=METAVIR F0–F1, Ishak 0–2, or equivalent.

a

Sample sizes and results restricted to patients with genotype 2 or 3 infection.

Sample sizes and results restricted to patients with genotype 2 or 3 infection.

From: Results

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.